Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Ophirex","sponsor":"AXA IM Prime Impact Master Fund","pharmaFlowCategory":"D","amount":"$37.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ophirex Completes $37 Million Series B Financing to Advance Development of Broad-Spectrum Snakebite Treatment","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by Ophirex

    Menu

    Ophirex

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Ophirex

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Ophirex Completes $37 Million Series B Financing to Advance Development of Broad-Spectrum Snakebite Treatment

              Details:

              Ophirex’s lead drug candidate, LY333013 (varespladib methyl), blocks sPLA2, a nearly ubiquitous and often highly toxic component of venom present in at least 95 percent of snake venoms.

              Lead Product(s): Varespladib Methyl

              Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: LY333013

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: AXA IM Prime Impact Master Fund

              Deal Size: $37.0 million Upfront Cash: Undisclosed

              Deal Type: Series B Financing January 05, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY